97183-75-0

Upstream product

• 462-06-6 fluorobenzene 
• 24376-18-9 3,4-dinitrobenzoyl chloride 
• 528-45-0 3,4-dinitrobenzoic acid 

Downstream Products

• 1026173-27-2 1-[2-Amino-3-(propane-2-sulfonyl)-3H-benzoimidazol-5-yl]-1-(4-fluoro-phenyl)-but-3-yn-1-ol 
• 186092-72-8 6-[(E)-1-(4-Methylsulfanyl-phenyl)-but-1-en-3-ynyl]-1-(propane-2-sulfonyl)-1H-benzoimidazol-2-ylamine 
• 180601-45-0 [2-Amino-3-(propane-2-sulfonyl)-3H-benzoimidazol-5-yl]-(4-methylsulfanyl-phenyl)-methanone 
• 180601-32-5 1-Isopropylsulfonyl-2-Amino-6-(4-Fluorobenzoyl)benzimidazole 
• 189061-08-3 Propane-2-sulfonic acid [2-amino-5-(4-methylsulfanyl-benzoyl)-phenyl]-amide 
• 180601-53-0 4-Amino-3-isopropylsulfonamido-4'-fluorobenzophenone 
• 66938-86-1 (3,4-diaminophenyl)(4-fluorophenyl)ketone 

Relevant academic research and scientific papers

Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime

A series of vinylacetylene analogs of Enviroxime (1) was synthesized. The new compounds are potent inhibitors of poliovirus in tissue culture. Cross-sensitivity with Enviroxime-derived mutants shows that the new compounds have the same mechanism of action as Enviroxime, which involves the viral 3A protein. In studies with Rhesus monkeys, the p-fluoro derivative 12 was found to be unique in providing oral bioavailability. Metabolism studies using hepatic microsomes suggest that this procedure would be a useful in vitro method for selecting the appropriate animal model for testing oral absorption. Compound 12 was found to be efficacious by oral administration in treating a Coxsackie A21 infection in CD-1 mice.